These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 17308149)

  • 21. The 'ART' of thrombosis: a review of arterial and venous thrombosis in assisted reproductive technology.
    Chan WS
    Curr Opin Obstet Gynecol; 2009 Jun; 21(3):207-18. PubMed ID: 19276806
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vascular endothelial growth factor production by circulating immune cells is elevated in ovarian hyperstimulation syndrome.
    Kosaka K; Fujiwara H; Yoshioka S; Fujii S
    Hum Reprod; 2007 Jun; 22(6):1647-51. PubMed ID: 17356124
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Role of intercellular adhesion molecule-1 and E-selectin in the pathogenesis of ovarian hyperstimulation syndrome].
    Kovachev E; Kozovski I; Markova V; Gemer O; Cherneva S
    Akush Ginekol (Sofiia); 2005; 44(4):26-31. PubMed ID: 16028375
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of gonadotropin-releasing hormone antagonists on the expression of vascular endothelial growth factor and its receptors in a rat model of ovarian hyperstimulation syndrome.
    Tong XM; Zhang SY; Song T; Xu WH; Lin XN; Shu J; Liu L
    Chin Med J (Engl); 2008 Dec; 121(23):2434-9. PubMed ID: 19102964
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Abnormal human chorionic gonadotropin levels and normal pregnancy outcomes in the ovarian hyperstimulation syndrome.
    Samuel MJ; Grosskinsky CM
    J Reprod Med; 2004 Jan; 49(1):8-12. PubMed ID: 14976788
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Soluble vascular endothelial-cadherin levels correlate with clinical and biological aspects of severe ovarian hyperstimulation syndrome.
    Villasante A; Pacheco A; Pau E; Ruiz A; Pellicer A; Garcia-Velasco JA
    Hum Reprod; 2008 Mar; 23(3):662-7. PubMed ID: 18216038
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of FSH receptor and CYP19A1 gene variations with sterility and ovarian hyperstimulation syndrome.
    Binder H; Dittrich R; Hager I; Müller A; Oeser S; Beckmann MW; Hamori M; Fasching PA; Strick R
    Reproduction; 2008 Jan; 135(1):107-16. PubMed ID: 18159088
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of ovarian hyperstimulation syndrome: new insights.
    Kasum M; Oresković S
    Acta Clin Croat; 2010 Dec; 49(4):421-7. PubMed ID: 21830453
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Intensive care for ovarian hyperstimulation syndrome].
    Shifman EM; Pogodin OK; Gumeniuk EG; Pogodin OO
    Anesteziol Reanimatol; 2007; (4):77-81. PubMed ID: 17929495
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Doxycycline inhibits vascular leakage and prevents ovarian hyperstimulation syndrome in a murine model.
    Fainaru O; Hornstein MD; Folkman J
    Fertil Steril; 2009 Nov; 92(5):1701-5. PubMed ID: 18937946
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum anti-Müllerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles.
    Lee TH; Liu CH; Huang CC; Wu YL; Shih YT; Ho HN; Yang YS; Lee MS
    Hum Reprod; 2008 Jan; 23(1):160-7. PubMed ID: 18000172
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A mutation in the follicle-stimulating hormone receptor as a cause of familial spontaneous ovarian hyperstimulation syndrome.
    Montanelli L; Delbaere A; Di Carlo C; Nappi C; Smits G; Vassart G; Costagliola S
    J Clin Endocrinol Metab; 2004 Apr; 89(4):1255-8. PubMed ID: 15080154
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A mutation in the follicle-stimulating hormone receptor as a cause of familial spontaneous ovarian hyperstimulation syndrome.
    Montanelli L; Delbaere A; Di Carlo C; Nappi C; Smits G; Vassart G; Costagliola S
    J Clin Endocrinol Metab; 2004 Mar; 89(3):1255-8. PubMed ID: 15001619
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ovarian hyperstimulation syndrome: A review for emergency clinicians.
    Timmons D; Montrief T; Koyfman A; Long B
    Am J Emerg Med; 2019 Aug; 37(8):1577-1584. PubMed ID: 31097257
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Spontaneous ovarian hyperstimulation syndrome and pituitary adenoma: incidental pregnancy triggers a catastrophic event.
    Baba T; Endo T; Kitajima Y; Kamiya H; Moriwaka O; Saito T
    Fertil Steril; 2009 Jul; 92(1):390.e1-3. PubMed ID: 19356755
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Removal of ascites up to 7.5 liters on one occasion and 45 liters in total may be safe in patients with severe ovarian hyperstimulation syndrome.
    Ozgun MT; Batukan C; Oner G; Uludag S; Aygen EM; Sahin Y
    Gynecol Endocrinol; 2008 Nov; 24(11):656-8. PubMed ID: 19031224
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Blood group and ovarian hyperstimulation syndrome.
    Bellver J; Ferrando M; Garrido N; Pellicer A
    Fertil Steril; 2010 Jan; 93(1):270-1. PubMed ID: 19683228
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacotherapy of ovarian hyperstimulation syndrome.
    Genazzani AR; Monteleone P; Papini F; Artini PG
    Expert Opin Pharmacother; 2010 Oct; 11(15):2527-34. PubMed ID: 20854183
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ovarian hyperstimulation syndrome.
    Avecillas JF; Falcone T; Arroliga AC
    Crit Care Clin; 2004 Oct; 20(4):679-95, ix. PubMed ID: 15388196
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Research on the protocol of limited ovarian stimulation to prevent ovarian hyperstimulation syndrome].
    Zhu YM; Gao HJ; He RH; Huang HF
    Zhonghua Fu Chan Ke Za Zhi; 2006 Nov; 41(11):740-4. PubMed ID: 17327030
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.